[
  {
    "ts": null,
    "headline": "BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.",
    "url": "https://finnhub.io/api/news?id=bd5f2b546a12945e0c479e3717bc3892eda85312db9beed5d50e0ca20e837ee7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736251200,
      "headline": "BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC",
      "id": 132311813,
      "image": "https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.",
      "url": "https://finnhub.io/api/news?id=bd5f2b546a12945e0c479e3717bc3892eda85312db9beed5d50e0ca20e837ee7"
    }
  }
]